51 articles for Z Feng
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
SAR exploration at the C-3 position of tetrahydro-ß-carboline sstr3 antagonists.
Merck Research Laboratories
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
Baylor College of Medicine
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.
Merck Research Laboratories
Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPAR¿.
Peking Union Medical College
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.
TBA
Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.
TBA
Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine.
Merck Research Laboratories
Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity.
Merck Research Laboratories
Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.
Merck Research Laboratories
Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib.
Chinese Academy of Medical Sciences
Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
Alcon Research
Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors.
University of Pittsburgh
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
Sun Yat-Sen University
Macrocarpal B blocks the binding between the phospholipase A2 receptor and its antibodies.
Peking University First Hospital
Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one" Scaffold for the Treatment of B Cell Lymphoma.
Shanghai Institute of Materia Medica
Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity.
China Pharmaceutical University
Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy.
Sichuan University
Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis.
China Pharmaceutical University
Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity.
Alcon Research
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.
Sun Yat-Sen University
Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases.
China Pharmaceutical University
Synthesis and structure-activity relationships of N - (3 - (1H-imidazol-2-yl) phenyl) - 3-phenylpropionamide derivatives as a novel class of covalent inhibitors of p97/VCP ATPase.
Chinese Academy of Medical Sciences and Peking Union Medical College
Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.
West China Hospital of Sichuan University
Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy.
Peking Union Medical College
Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3.
Sun Yat-Sen University
Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis.
China Pharmaceutical University
Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.
Sichuan University-University of Oxford Huaxi Joint Centre For Gastrointestinal Cancer
Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer.
Sichuan University
Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
Peking Union Medical College
Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
China Pharmaceutical University
Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors.
Sichuan University
Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
Peking Union Medical College
Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
Peking Union Medical College
Structural and in Vitro Functional Characterization of a Menthyl TRPM8 Antagonist Indicates Species-Dependent Regulation.
Marshall University
Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
Sichuan University and Collaborative Innovation Center
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).
F. Hoffmann-La Roche
Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors.
Merck
COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF
Reiley Pharmaceuticals
SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF
Changchun Genescience Pharmaceutical Co.
COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Chong Kun Dang Pharmaceutical
Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors
Sumitomo Dainippon Pharma Oncology
Substituted triazolopyridines and their use as TTK inhibitors
Bayer Pharma Aktiengesellschaft
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.
The R. W. Johnson Pharmaceutical Research Institute